id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9678 R34453 |
Tomson (Carbamazepine), 2018 | Neural tube defects | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 9.02 [1.11;73.39] C | 7/1,957 1/2,514 | 8 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9655 R34366 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Neural tube defect | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.54 [0.46;13.86] C | 4/1,657 2/2,098 | 6 | 1,657 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10290 R37673 |
Vajda (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Neural Tube Malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.62 [0.11;64.66] C excluded (control group) |
1/361 0/315 | 1 | 361 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10291 R37679 |
Vajda (Carbamazepine) (Controls unexposed, sick), 2013 | Neural Tube Malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.22 [0.05;30.19] C | 1/361 0/147 | 1 | 361 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9619 R34195 |
Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 | Neural tube defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 2.27 [0.38;13.62] C | 3/1,033 2/1,562 | 5 | 1,033 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9653 R34358 |
Bànhidy (Carbamazepine), 2011 | Neural tube defects | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 2.00 [0.16;25.76] C | 2/12 1/11 | 3 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9628 R35306 |
Mawer (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Neural Tube Malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.56 [0.01;28.68] C excluded (control group) |
0/66 0/37 | 0 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9629 R35310 |
Mawer (Carbamazepine) (Controls unexposed, disease free), 2010 | Neural Tube Malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.44 [0.06;35.82] C excluded (control group) |
0/66 1/285 | 1 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9630 R35314 |
Mawer (Carbamazepine) (Controls unexposed, sick), 2010 | Neural Tube Malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.62 [0.01;31.78] C | 0/66 0/41 | 0 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9657 R34384 |
Canger (Carbamazepine), 1999 | Neural tube defects | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.66 [0.03;16.67] C | 1/113 0/25 | 1 | 113 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 2.40 [1.00;5.77] | 24 | 5,199 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls exposed to Lamotrigine, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Controls exposed to Lamotrigine, sick; 5: Carbamazepine; 6: Carbamazepine) (Controls unexposed, sick; 7: Carbamazepine;
Asymetry test p-value = 0.1440 (by Egger's regression)
slope=2.4380 (0.9415); intercept=-1.3746 (0.7942); t=1.7309; p=0.1440
excluded 9628, 9629, 10290